Quince Therapeutics Inc. has announced its participation in the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society in the United Kingdom. During the event, Quince will provide updates on its pivotal Phase 3 NEAT clinical trial, which is focused on evaluating the neurological effects of eDSP treatment in patients with Ataxia-Telangiectasia (A-T). The trial, currently in the enrollment phase, has secured 99 participants to date. Key opinion leaders at the conference will present post hoc data analyses from Quince's prior Phase 3 ATTeST clinical trial. Topline results from the NEAT trial are expected to be reported in the first quarter of 2026, with a potential New Drug Application (NDA) submission to the FDA anticipated in the second half of 2026, contingent on positive outcomes.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。